• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Almac Group

    PCI Pharma Services

    Adare Pharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Emergent BioSolutions

    Aphena Pharma Solutions

    Almac Group

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Will Immunotherapy Knock Out Cancer?

    Innovative immunotherapy companies discuss with WuXi AppTec what’s next for this rapidly developing field ahead of BIO 2017.

    Will Immunotherapy Knock Out Cancer?
    Related CONTENT
    • Alkermes, Merck Enter Clinical Trial and Supply Agreement
    • CordenPharma Enters Alliance with Nanos of South Korea
    • Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio
    • Ajinomoto, Bright Peak Enter Immunocytokines Research Pact
    • SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax
    06.14.17
    The answer to the question is yes, and no.

    Advances in just the past five years have proven immunotherapy can stimulate the immune system’s natural capabilities to kill cancer cells, and possibly lead to cures for many patients. So yes, it appears immunotherapy is the best weapon yet against cancer and is poised to deliver a knockout blow to this deadly disease.

    But, no, it is doubtful it can achieve such an historic milestone on its own. Many experts believe that combinations of different kinds of immunotherapies, along with traditional chemotherapies and radiation, ultimately will emerge as the most effective strategies.

    Although early successes have raised hopes for a widespread cure, it also remains unclear whether even powerful combinations can elicit that outcome for all cancer patients. What seems apparent, however, is that combination therapies will be able to transform cancer, particularly advanced forms of the disease, from a rapid killer into a manageable chronic condition, giving patients many more years and improved quality of life.

    For this article, WuXi AppTec spoke with leading immunotherapy experts about the prospects of conquering the many forms of cancer. They include MPM managing director, Christiana Bardon; Juno Therapeutics chief executive officer Hans Bishop; Kineta chief executive officer, Shawn Iadonato; TCR2 Therapeutics chief executive officer, Garry Menzel; and Advaxis Immunotherapies chief executive officer, Daniel O’Connor.

    Background

    The idea of cancer immunotherapy has been around for a century. The challenge to its effectiveness has been discovering how to reprogram the immune system’s frustrating lack of interest in dispensing with a deadly anomaly that sits in plain view.

    Recent advances in genomics and the discovery of biomarkers related to the disease’s sleight-of-hand in evading detection have escalated expectations that immunotherapy finally is ready to fully enlist the immune system in the war on cancer. The level of excitement over immunotherapy has reached a fever pitch, stoked over the past several years by clinical research data and new drug approvals demonstrating impressive successes. This optimism lies in the confidence that the science of understanding how the immune system works is poised for significantly greater breakthroughs within the next 10 years.

    The prospect that a single immunotherapy will dominate in supplanting traditional, standard-of-care chemotherapies and radiation is motivating mega-wagers by public and private investors, seeking to pick the winners among the score of drug developers emerging in this highly competitive field.

    Many experts, however, are hedging their bets, forecasting an assault by a combination of immunotherapies, alongside chemotherapy and radiation, to overwhelm a stubborn killer ranked by the World Health Organization (WHO) as the second leading cause of death globally with an annual economic cost of $1.2 trillion.

    Where are we now?

    There is no doubt immunotherapy has been broadly embraced as not only “the next big thing” in cancer treatment, but also the best hope yet for a cure among everyone from bench scientists to long-suffering patients. The U.S. National Cancer Institute has described cancer immunotherapy as a transformative technology and a central element of the federal government’s Cancer Moonshot.

    The American Society of Clinical Oncology named immunotherapy as the clinical advance of the year in 2016 and 2017. More than 130 biotech and 20 Big Pharma companies are developing cancer immunotherapy drugs with worldwide sales expected to hit $40 billion in just three years, according to a recent report from Tufts Center for the Study of Drug Development. Immunotherapies are beginning to dominate public and private cancer research funding, drug approvals and, of course, the attention of the public and news media.

    The goal of harnessing the immune system to destroy cancer took a major step forward in 2011 with FDA approval of the first checkpoint inhibitor. In the past five years, five checkpoint inhibitors, which are monoclonal antibodies that enable T cells to recognize and attack cancer cells, have been approved for eight types of cancer.

    Other forms of immunotherapy include:

    • Adoptive cell therapy, in which cancer killing T cells are stimulated to attack tumors;
    • Small molecule immune modulators that elicit immunogenic cell death;
    • Cancer vaccines, which introduce cancer antigens into the body to generate an immune system response;
    • Oncolytic viruses, which infect and kill cancer cells; and
    • Oncolytic bacteria, which are vectors that deliver cancer antigens to boost the immune systems attack on the disease.

    The enthusiasm about the prospect of a cure certainly is not misplaced, and arguably is not overhyped, as most experts agree they have their proof of concept with checkpoint inhibitors. More effective treatments are within sight as scientists are just beginning to understand how the immune-genome works with the revelation of more and more biomarkers related to such a complex and varied disease.

    “Checkpoint inhibitors are the most effective immunotherapy approaches to date,” says Christiana Bardon, M.D., managing director of MPM’s Oncology Impact Fund.

    Four of the five new immunotherapy drugs inhibit PD-1/PD-L1, which are proteins on T cells that prevent them from attacking other cells, including cancer cells. They have elicited long-term complete responses, essentially cures, in 20% of patients, Bardon notes. That’s a huge improvement over the 5% to 10% of patients whose cancers are destroyed by chemotherapy.”

    But it’s not enough, Bardon says. “There are still many patients who don’t respond to these PD-1 inhibitors and we need to understand why. The second thing is that not all cancers respond to checkpoint inhibition.”

    These approved checkpoint inhibitors are made and marketed by the traditional big pharma companies and represent the first generation of new immunotherapy approaches. A sampling of other strategies being pursued by the hundreds of smaller biotech companies reveals the broad scope of new therapies under development and underscores the enormous excitement immunotherapies engender.

    For example, Juno Therapeutics uses an adoptive cell therapy approach, such as CAR-T cell therapies, which involves engineering T cells to seek and destroy cancer cells.

    Juno CEO Hans Bishop says, “We are working on multiple fronts to build on what we have done to date, including focusing on keeping engineered T cells active in the body for a longer period of time; controlling elements of cell expansion in order to improve tolerability; and better understanding what types of cells work best, cell signaling, and how to better equip cells to find cancer.”

    Advaxis Immunotherapies alters a live strain of Listeria monocytogenes (Lm) bacteria to stimulate a T cell response against cancer. CEO Daniel J. O’Connor says Advaxis has learned a “great deal about immune tolerance and the multiple mechanisms that protect cancer cells, but we do not know them all. Two elements that protect cancer in the tumor microenvironment that we do know well are regulatory T cells and myeloid-derived suppressor cells that have the ability to shut down a T cell response.”

    Kineta’s approach focuses on the innate immune system, which is different from the adaptive immune system that characterizes T cell responses unleashed by the checkpoint inhibitors. CEO Shawn Iadonato says his company is developing small molecule compounds that target RIG-1 like receptors, including RIG-1 and MDA5.

    “Targeting these innate immune pathways is a differentiated strategy that can cause immunogenic cell death, elicit neoantigen responses and turn a cold tumor hot,” Iadonato explains. “They are small molecule drugs that can enable rapid drug development and may be dosed orally or systemically.”

    TCR2 Therapeutics is developing a different kind of T cell stimulating therapy aimed at solid tumors.

    “The T cell receptor (TCR) is a remarkably complex structure that triggers a cascade of biological pathways when bound to a tumor antigen,” explains CEO Garry Menzel. “We seek to harness all of that power by tethering a TCR subunit to a specific antigen binding domain. The key is that this construct is integrated into the TCR so that any signaling on binding the tumor antigen triggers the entire activation cascade rather than only part of it.”

    The swiftness of progress in developing immunotherapies is mindboggling and, of course, the reason for all the enthusiasm.

    “Only in the last five years,”Bardon notes, “have we figured out that the immune system plays a role. Now there are hundreds and thousands of ways to apply that science and that thinking toward developing new therapies.”

    In May 2017, nearly 1,300 cancer immunotherapy clinical studies were listed on the U.S. National Institutes of Health’s ClinicalTrials.gov website. Three years ago, a Nature article estimated that within 10 years, 60 percent of patients with advanced cancer will be treated with immunotherapies.

    Where are we headed?

    For starters, the immunotherapy field will continue to be dominated by pioneering, risk-taking biotech companies conducting the hard work of innovation with big pharma selecting the best in putting together the most effective combination therapies.

    “The truth is that smaller companies are more nimble and more aggressive in bringing innovation to the clinic,” Bardon says.

    In the long run, however, Bardon believes the Big Pharmas and Big Biotechs with their extensive resources and marketing capabilities will absorb the smaller companies in an aggressive competition to become the lead combination therapy provider. The driver is a potential market for cancer treatments whose upside seems unlimited. For example, Mr. Bardon observes, the PD-1 checkpoint inhibitors, the first generation of new immunotherapies, are expected to generate a $20 billion market opportunity.

    The investor frenzy over cancer immunotherapy companies is reminiscent of the overly optimistic excitement at the turn of the last century that was heaped on emerging companies attempting to take advantage of the new science of genomics. Many in the patient, investor and research communities were disappointed by overpromised outcomes.

    The differences this time around are the dramatic scientific progress in understanding genomics that has occurred in nearly two decades since the full human genome was sequenced and the drug industry’s experience in better managing expectations.

    “The clinical data,” says TCR2’s Menzel, “clearly demonstrate that we have entered a new golden age of therapies following mixed success with surgery, radiology and chemotherapy.”
    But he notes, “The immune system is very complex and we need a better understanding of how it interacts with tumor cells to enable the very best therapies for patients.”

    Juno’s Bishop agrees, saying, “Cancer has a remarkable ability to adapt and evade treatment, and we are relatively early as a field in learning how to harness the potential and adaptability of the immune system to fight this disease.”

    For example, while CAR-T therapies, which have generated the most enthusiasm following the success of checkpoint inhibitors, have shown “emerging efficacy” in blood cancers, Bardon says, “We haven’t see any efficacy with CAR-T in solid tumors.”

    Another major determinant in the future of immunotherapy involves the realization that combination therapies will be required to break up the mysterious dances between the immune-genome and cancer, choreographed by the differences among cancer types and population groups.

    Advaxis’ O’Connor sees two trends emerging.

    “First, given the complexities and multiple layers of the immune system and tumor microenvironment, we know the potential of combination therapies holds significant promise,” he explains. “Second, and even more exciting, we see a move away from the one-size-fits-all approach to treating disease as we start to focus more and more on bringing patients personalized therapies tailored to their specific cancers.”

    Whether the science can lead to cures for everyone remains far from settled, particularly for patients with advanced, metastatic cancer. However, the experience with the first generation of immunotherapies demonstrates the potential for disarming a killer and significantly improving patients’ quality of life.

    As Kineta’s Iadonato observes, “Immunotherapy provides the promise that we can move cancer to being treated as a chronic disease and not simply trying to extend survival.”

    Bardon has talked to investors who have seen the powerful efficacy of checkpoint inhibitors and believe a widespread cure for the disease is imminent. “My response,” she says, is “there is still work to be done. I don’t think in my lifetime, we will cure everybody’s cancer, and every type of cancer.”

    Bishop also observes, “Our understanding of these products will grow exponentially over the next five years. In five years’ time we expect to begin implementing next-generation strategies that expand the number of patients we can treat, the number of cancers we can target, and the depth and duration of remissions we can begin to expect.”

    What challenges do we face?

    The scientific challenges of discovering effective new immunotherapies attract most of the attention. But other equally significant challenges involve delivering these therapies to patients. Foremost among them is the design of clinical trials and market pricing. Immunotherapies are targeted to specific biomarkers that vary from cancer to cancer and patient to patient. They are the latest in what was first called personalized medicine and is now referred to as precision medicine.

    The challenge for clinical trial designers is that these therapies often reveal significant efficacy in Phase I and II studies involving small numbers of patients. These trials were primarily designed to assess safety and initial evidence of efficacy. The gold standard for efficacy to determine if a medicine can replace standard-of-care is the Phase III trial, which involves many more patients who are randomized to receive either the drug or a placebo.

    In addition, subjects in these trials have advanced cancers with no other treatment options. They know what these new therapies can accomplish and they are refusing to participate in placebo-controlled trials. They want to receive the study drug or drugs. This challenge to clinical trial design has generated calls for engaging patients as active partners in clinical trials rather than treating them as passive research subjects. It also has raised serious doubts about the traditional ethical justification for enrolling patients in randomized, placebo-controlled studies.

    Government, academic and industry scientists also have pushed for earlier approval of these targeted therapies based on preliminary efficacy findings to avoid expensive Phase III studies. The FDA has implemented expedited approvals for drugs it designates as breakthroughs without requiring randomization studies. Other experts have suggested relying on studies involving larger numbers of patients, all of whom receive the study drug.

    A 2016 article in Cancer Treatment Reviews concluded, “In this current era of personalized and targeted medicine, systematic evaluation and development of new design strategies, both for early phase and definitive trials, will continue to be required for proper clinical validation of tailored tests and treatments.”

    As for market pricing, industry experts acknowledge it is an issue, which no longer can be ignored.

    “We need to build the capabilities to reliably produce these drugs at scale with a distribution and re-imbursement framework that fosters access to broad populations across the globe,” says Juno’s Bishop.

    Advaxis’ O’Connor adds, “We are sensitive to the financial burden our cancer patients and families endure and believe our industry needs to take a hard look at where efficiencies can be achieved that will balance the need for industry to recoup product development expenses while also funding the development and advancement of new product candidates to market.”

    The projected high cost of immunotherapies also is putting increasing pressure on companies to produce significant, not just incremental, positive outcomes for patients.

    “People are willing to pay for a treatment if you can cure their cancer or convert their cancer to a chronic disease. From that perspective you have to swing for the fences to make sure you’re going to have meaningful impact for patients and make sure that the system can find value in your therapy,” Bardon suggests. CP

    Author: WuXi AppTec content team. For more information or to read other expert interviews, please visit wxpress.wuxiapptec.com. 
    Related Searches
    • immunotherapies
    • fda
    • pharma companies
    • biotech
    Suggested For You
    Alkermes, Merck Enter Clinical Trial and Supply Agreement Alkermes, Merck Enter Clinical Trial and Supply Agreement
    CordenPharma Enters Alliance with Nanos of South Korea CordenPharma Enters Alliance with Nanos of South Korea
    Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio
    Ajinomoto, Bright Peak Enter Immunocytokines Research Pact Ajinomoto, Bright Peak Enter Immunocytokines Research Pact
    SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax
    BioVaxys, Wuxi Biologics Enter Bioproduction Agreement BioVaxys, Wuxi Biologics Enter Bioproduction Agreement
    Outsourcing Solid Dosage Manufacturing Outsourcing Solid Dosage Manufacturing
    Selexis SA and BITT Enter Service Agreement Selexis SA and BITT Enter Service Agreement
    NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein
    Amgen to Acquire Five Prime Therapeutics for $1.9B Amgen to Acquire Five Prime Therapeutics for $1.9B
    Fusion Pharmaceuticals Acquires IPN-1087 Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial Strata Oncology Unveils Strata PATH Trial
    Q BioMed Inks Strontium89 Supply Pact Q BioMed Inks Strontium89 Supply Pact
    J&J’s Single-Dose COVID-19 Vax Issued EUA J&J’s Single-Dose COVID-19 Vax Issued EUA
    BMS Expands Cell Therapy Manufacturing Capabilities BMS Expands Cell Therapy Manufacturing Capabilities

    Related Online Exclusives

    • Biologics, Proteins, Vaccines | cGMP Manufacture
      Advanced Analytics Advancing Development of Genetic Vaccines

      Advanced Analytics Advancing Development of Genetic Vaccines

      Leveraging innovative advanced analytical technologies to ensure regulatory compliance in the development and production of novel vaccines.
      Kristin Brooks, Managing Editor, Contract Pharma 03.29.21

    • Biologics, Proteins, Vaccines | Clinical Trials
      Inside a COVID Vaccine Trial

      Inside a COVID Vaccine Trial

      Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
      Kristin Brooks, Managing Editor 02.05.21

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      The Future of Vaccines and Biologics

      The Future of Vaccines and Biologics

      Dr. Linda Marbán of Capricor Therapeutics discusses the advances in responding to infectious diseases.
      Kristin Brooks, Managing Editor, Contract Pharma 02.04.21


    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Biologics, Proteins, Vaccines
      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines

      CMOs expand and ‘repurpose’ capacities.
      S Harachand, Contributing Editor 10.20.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20


    • Biologics, Proteins, Vaccines | Drug Discovery
      Cell Therapy for Solid Tumors

      Cell Therapy for Solid Tumors

      Is base editing the solution for solid tumor-based cell therapy?
      Jonathan Frampton, Corporate Development Partner, Horizon Discovery 06.26.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20


    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      COVID-19 Vaccine Response

      COVID-19 Vaccine Response

      ICON execs discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine
      Kristin Brooks, Contract Pharma 04.01.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trial Materials | Drug Development
      Newsmakers: Thermo Fisher Scientific

      Newsmakers: Thermo Fisher Scientific

      Leon Wyszkowski discusses the company’s recent investments, the challenges biopharma companies face, and future needs in the outsourcing space
      03.16.20

    • Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development
      COVID-19 Clinical Trials

      COVID-19 Clinical Trials

      The vaccines in development for COVID-19, who's developing them, and where they stand in the development process
      Kristin Brooks, Contract Pharma 03.10.20


    • Bio News | Biologics, Proteins, Vaccines | cGMP Manufacture
      Newsmakers: Vigene Biosciences

      Newsmakers: Vigene Biosciences

      Dr. Jeffrey Hung, Chief Commercial Officer, discusses Vigene’s new $20 million lab and strategic partnership with ASC Therapeutics
      Kristin Brooks, Contract Pharma 02.20.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Industry News
      Outsourcing in the Cell & Gene Therapy Space

      Outsourcing in the Cell & Gene Therapy Space

      Specialized and coordinated capabilities aim to accelerate drug development and reduce risk for sponsors
      Kristin Brooks, Contract Pharma 02.04.20

    • Aseptic Processing | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish | Parenterals
      Contract Pharma’s 20th Anniversary Series: Vetter

      Contract Pharma’s 20th Anniversary Series: Vetter

      Oskar Gold of Vetter discusses vital changes in the industry and the science and technology needed to support advanced therapeutics
      Kristin Brooks, Contract Pharma 11.13.19

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    The Honest Company Files for IPO
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login